Physician profile
Robert E Weltman
NPI 1720119928
$828.80
in general payments reported to CMS, 2019-2025
16 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.55 · 2021: $197 · 2022: $150 · 2023: $109 · 2024: $170 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $193.88 | 2022-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $95.09 | 2021-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $83.54 | 2021-2022 | |
| Lilly USA, LLC | $69.30 | 2021-2024 | Olumiant |
| Amgen INC. | $54.65 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $47.58 | 2023-2025 | |
| Incyte Corporation | $46.84 | 2022 | |
| Sun Pharmaceutical Industries INC. | $42.21 | 2022-2025 | |
| Genzyme Corporation | $33.23 | 2025 | |
| Galderma Laboratories, L.P. | $31.27 | 2021-2022 | |
| Dermira, INC. | $28.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.25 | 2023 | Spevigo |
| Leo Pharma INC. | $21.37 | 2025 | Adbry |
| Verrica Pharmaceuticals INC. | $20.85 | 2024 | Ycanth |
| Cipher Pharmaceuticals US LLC | $20.19 | 2025 | Natroba, Spinosad |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weltman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.